NCT04623892 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

TQB2618 injection

TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.

Trial Locations (1)

310022

Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou